Merck’s Welireg receives European approval for two indications
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Subscribe To Our Newsletter & Stay Updated